Court: Drugmaker can be held responsible for generic-label omission

The Alabama Supreme Court ruled Pfizer can be held liable for safety information omitted from a generic version of its Reglan heartburn drug, writing that omissions or other problems with brand-name drug labels "would necessarily be repeated" on corresponding generic drug labels.

View Full Article in:

New York Times (tiered subscription model), The ·

Published in Briefs: